Olr749 inhibitors represent a class of chemical compounds specifically designed to modulate the activity of the Olr749 receptor, a member of the olfactory receptor family. These receptors, part of the larger G-protein coupled receptor (GPCR) superfamily, are primarily involved in the detection of odorants, playing a crucial role in the olfactory system. Olr749, in particular, is expressed in olfactory sensory neurons and is responsible for binding specific odorant molecules, initiating a cascade of intracellular events that ultimately lead to the perception of smell. The inhibition of Olr749 involves the binding of inhibitors to this receptor, preventing it from interacting with its natural ligands. This blockade can help in elucidating the receptor's structure-function relationship, as well as its role in olfactory signal transduction and neural coding of olfactory information.
Structurally, Olr749 inhibitors can vary widely, including small organic molecules, peptides, or more complex synthetic compounds. These inhibitors are often characterized by their ability to bind with high affinity to the Olr749 receptor, often determined through in vitro assays using receptor-expressing cells. Advanced computational modeling techniques such as molecular docking and dynamics simulations are employed to predict and optimize the binding interactions between inhibitors and the Olr749 receptor. By studying these interactions, researchers gain valuable insights into the molecular determinants of receptor-ligand specificity and receptor activation mechanisms. Furthermore, Olr749 inhibitors serve as important tools in chemical biology, enabling the dissection of olfactory signaling pathways and contributing to our understanding of the molecular basis of olfaction. This knowledge can inform the broader study of GPCR biology, as olfactory receptors share structural and functional characteristics with other receptors in this superfamily.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor, potentially affecting proteins in the MAPK/ERK pathway. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
BCL-2 inhibitor, potentially impacting apoptosis-regulating proteins. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
MEK inhibitor, potentially disrupting proteins in the MAPK/ERK pathway. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
VEGFR, EGFR, and RET inhibitor, potentially affecting proteins in associated signaling pathways. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
PI3Kδ inhibitor, potentially impacting proteins in B-cell signaling pathways. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
BTK inhibitor, potentially affecting proteins in B-cell signaling pathways. | ||||||
Rucaparib | 283173-50-2 | sc-507419 | 5 mg | $150.00 | ||
PARP inhibitor, potentially disrupting DNA repair and affecting associated protein pathways. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $176.00 $235.00 $281.00 $339.00 | 9 | |
PI3K inhibitor, potentially impacting proteins in PI3K/AKT/mTOR signaling pathways. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
MEK inhibitor, potentially affecting proteins in the MAPK/ERK pathway. | ||||||
BAY 80-6946 | 1032568-63-0 | sc-503264 | 5 mg | $562.00 | ||
PI3K inhibitor, potentially disrupting proteins in PI3K/AKT/mTOR signaling pathways. | ||||||